Cover Image
Market Research Report
Product code 
1037013

Pharmerging Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

Published: | IMARC Services Private Limited | 143 Pages | Delivery time: 2-3 business days

Price

Back to Top
Pharmerging Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026
Published: November 10, 2021
IMARC Services Private Limited
Content info: 143 Pages
Delivery time: 2-3 business days
  • ALL
  • Description
  • Table of Contents
Description

The global pharmerging market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 10.4% during 2021-2026. Pharmerging refers to a group of countries that hold low positioning in the pharmaceutical market but have a speedy growth. Some of the key pharmerging markets include China, India, Brazil, Russia, South Africa, Mexico, Indonesia, Turkey, etc.

The increasing healthcare expenditures along with the rising number of private hospitals are currently propelling the global pharmerging market growth. Additionally, the high prevalence of numerous chronic diseases and growing consumer awareness towards early disease detection and treatment procedures are further augmenting the market growth. Moreover, the increasing geriatric population, who are more prone to serious medical conditions, such as dementia, hypertension, cardiac failure, etc., is also bolstering the demand for pharmaceuticals. Additionally, the introduction of government policies and reimbursement schemes across various countries for reducing the cost of treatment for chronic diseases is also propelling the market growth. Moreover, the growing number of insurance companies in the pharmerging countries offering numerous insurance policies to decrease the out-of-the-pocket expenditures is further augmenting the demand of pharmaceuticals in these countries. Apart from this, the rising investments in extensive R&D activities in the fields of biotechnology, immunology, oncology, etc., for the introduction of advanced treatments are also catalyzing the market growth.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global pharmerging market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, product outlook, indication and distribution channel.

Breakup by Product Outlook:

  • Pharmaceuticals
  • Patented Prescription Drugs
  • Generic Prescription Drugs
  • OTC Drugs
  • Healthcare
  • Medical Devices
  • Clinical Diagnosis
  • Others

Breakup by Indication:

  • Lifestyle Diseases
  • Cancer and Autoimmune Diseases
  • Infectious Diseases
  • Others

Breakup by Distribution Channel:

  • Hospitals
  • Retail Pharmacies
  • Online Stores
  • Others

Breakup by Country:

  • Tier I
  • China
  • Tier II
  • India
  • Brazil
  • Russia
  • South Africa
  • Tier II
  • Argentina
  • Mexico
  • Poland
  • Ukraine
  • Turkey
  • Saudi Arabia
  • Egypt
  • Algeria
  • Nigeria
  • Thailand
  • Indonesia
  • Pakistan
  • Others

Competitive Landscape:

  • The competitive landscape of the industry has also been examined with some of the key players being Sanofi S.A., Pfizer Inc., AstraZeneca Plc, GlaxoSmithKline Plc, F. Hoffmann-La Roche AG (Roche AG), Eli Lilly and Company, Johnson & Johnson, Abbott Laboratories, Novartis AG and Teva Pharmaceutical Limited.

Key Questions Answered in This Report:

  • How has the global pharmerging market performed so far and how will it perform in the coming years?
  • What are the key regional markets?
  • What is the impact of COVID-19 on global pharmerging market?
  • What is the breakup of the market based on the product outlook?
  • What is the breakup of the market based on the indication?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the market?
  • What is the structure of the global pharmerging market and who are the key players?
  • What is the degree of competition in the market?
Table of Contents
Product Code: SR1020G31_Report

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pharmerging Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Pharmaceutical
    • 6.1.1 Market Trends
    • 6.1.2 Major Types
      • 6.1.2.1 Patented Prescription Drugs
      • 6.1.2.2 Generic Prescription Drugs
      • 6.1.2.3 OTC Drugs
    • 6.1.3 Market Forecast
  • 6.2 Healthcare
    • 6.2.1 Market Trends
    • 6.2.2 Major Types
      • 6.2.2.1 Medical Devices
      • 6.2.2.2 Clinical Diagnosis
      • 6.2.2.3 Others
    • 6.2.3 Market Forecast

7 Market Breakup by Indication

  • 7.1 Lifestyle Diseases
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cancer and Autoimmune Diseases
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Infectious Diseases
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Country

  • 9.1 Tier I
    • 9.1.1 China
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
  • 9.2 Tier II
    • 9.2.1 India
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Brazil
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 Russia
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Africa
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
  • 9.3 Tier III
    • 9.3.1 Argentina
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 Mexico
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 Poland
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Ukraine
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Turkey
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Saudi Arabia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Egypt
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
    • 9.3.8 Algeria
      • 9.3.8.1 Market Trends
      • 9.3.8.2 Market Forecast
    • 9.3.9 Nigeria
      • 9.3.9.1 Market Trends
      • 9.3.9.2 Market Forecast
    • 9.3.10 Thailand
      • 9.3.10.1 Market Trends
      • 9.3.10.2 Market Forecast
    • 9.3.11 Indonesia
      • 9.3.11.1 Market Trends
      • 9.3.11.2 Market Forecast
    • 9.3.12 Pakistan
      • 9.3.12.1 Market Trends
      • 9.3.12.2 Market Forecast
    • 9.3.13 Others
      • 9.3.13.1 Market Trends
      • 9.3.13.2 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Sanofi S.A.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Pfizer Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 AstraZeneca Plc.
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 GlaxoSmithKline Plc.
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.3 SWOT Analysis
    • 13.3.5 F. Hoffmann-La Roche AG (Roche AG)
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Eli Lilly and Company
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Johnson & Johnson
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Abbott Laboratories
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Novartis AG
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Teva Pharmaceutical Limited
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financial
      • 13.3.10.4 SWOT Analysis